Genaera Liquidating Trust (MEDI-528) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Genaera Liquidating Trust (MEDI-528) General Information
Description
A portfolio of intellectual property rights. The portfolio includes certain intellectual property and interests in future milestones and royalties for MEDI-528, an IL-9 antibody program under development by AstraZeneca's subsidiary, MedImmune.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Commercial Products
Acquirer
Primary Office
- 5110 Campus Drive
- Plymouth Meeting, PA 19462
- United States
Genaera Liquidating Trust (MEDI-528) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genaera Liquidating Trust (MEDI-528) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|